Eleonora Cannas

Ms. Eleonora Cannas

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 October 2023 in Molecular Cancer Therapeutics
Verified
Journal Article
Closed access
PDF file
ARAlberto Arribas Romano
Alberto Arribas Romano
SNSara Napoli
Sara Napoli
Luciano CascioneLuciano Cascione
Luciano Cascione
LBLaura Barnabei
Laura Barnabei
GSGiulio Sartori
Giulio Sartori
Francesco BertoniFrancesco Bertoni
Francesco Bertoni
BTK and PI3K inhibitors are among the drugs approved for the treatment of patients with lymphoid neoplasms. Although active, their ability to lead to long-lasting complete remission is rather limited, especially in the lymphoma setting. This indicates that tumor cells often develop resistance to the drugs. We started from a marginal zone lymphoma cell line, Karpas-1718, kept under prolonged exposure to the PI3Kδ inhibitor idelalisib until acquisition of resistance, or with no drug. Cells underwent transcriptome, miRNA and methylation profiling, whole-exome sequencing, and pharmacologic screening, which led to the identification of the overexpression of ERBB4 and its ligands HBEGF and NRG2 in the resistant cells. Cellular and genetic experiments demonstrated the involvement of this axis in blocking the antitumor activity of various BTK/PI3K inhibitors, currently used in the clinical setting. Addition of recombinant HBEGF induced resistance to BTK/PI3K inhibitors in parental cells and in additional lymphoma models. Combination with the ERBB inhibitor lapatinib was beneficial in resistant cells and in other lymphoma models already expressing the identified resistance factors. An epigenetic reprogramming sustained the expression of the resistance-related factors, and pretreatment with demethylating agents or EZH2 inhibitors overcame the resistance. Resistance factors were also shown to be expressed in clinical specimens. In conclusion, we showed that the overexpression of ERBB4 and its ligands represents a novel mechanism of resistance for lymphoma cells to bypass the antitumor activity of BTK and PI3K inhibitors and that targeted pharmacologic interventions can restore sensitivity to the small molecules.

13 December 2024 in Blood Advances
Verified
Journal Article
Open access
PDF file
ARAlberto Arribas Romano
Alberto Arribas Romano
SNSara Napoli
Sara Napoli
EGEugenio Gaudio
Eugenio Gaudio
CHCharles Herbaux
Charles Herbaux
ECEleonora Cannas
Eleonora Cannas
Francesco BertoniFrancesco Bertoni
Francesco Bertoni
CD37-directed antibody and cellular-based approaches have shown preclinical and promising early clinical activity. Naratuximab emtansine (Debio 1562; IMGN529) is an antibody-drug conjugate (ADC) incorporating an anti-CD37 monoclonal antibody conjugated to the maytansinoid DM1 as payload, with activity as a single agent and in combination with rituximab in patients with lymphoma. We studied naratuximab emtansine and its free payload in 54 lymphoma models, correlated its activity with CD37 expression, characterized two resistance mechanisms, and identified combination partners providing synergy. The activity, primarily cytotoxic, was more potent in B- than T-cell lymphoma cell lines. After prolonged exposure to the ADC, one diffuse large B-cell lymphoma (DLBCL) cell line developed resistance to the ADC due to the CD37 gene biallelic loss. After CD37 loss, we also observed upregulation of interleukin-6 (IL-6) and related transcripts. Recombinant IL-6 led to resistance. Anti-IL-6 antibody tocilizumab improved the ADC’s cytotoxic activity in CD37+ cells. In a second model, resistance was sustained by a PIK3CD activating mutation, with increased sensitivity to PI3Kδ inhibition and a functional dependence switch from MCL1 to BCL2. Adding idelalisib or venetoclax overcame resistance in the resistant derivative and improved cytotoxic activity in the parental cells. In conclusion, targeting B-cell lymphoma with the naratuximab emtansine showed vigorous antitumor activity as a single agent, which was also observed in models bearing genetic lesions associated with inferior outcomes, such as Myc Proto-Oncogene (MYC) translocations and TP53 inactivation or R-CHOP (rituximab, cyclophosphamide, doxorubicin, Oncovin [vincristine], and prednisone) resistance. Resistant DLBCL models identified active combinations of naratuximab emtansine with drugs targeting IL-6, PI3Kδ, and BCL2.

29 May 2026 in Blood
Verified
Journal Article
Closed access
PDF file
ARAlberto Arribas Romano
Alberto Arribas Romano
ECEleonora Cannas
Eleonora Cannas
GSGiulio Sartori
Giulio Sartori
FGFrancesca Guidetti
Francesca Guidetti
Luciano CascioneLuciano Cascione
Luciano Cascione
Francesco BertoniFrancesco Bertoni
Francesco Bertoni
Resistance to Bruton tyrosine kinase (BTK) inhibitors remains a major clinical challenge in B-cell lymphomas and often occurs in the absence of BTK or PLCG2 mutations. Here, we investigated non-genetic mechanisms of ibrutinib resistance in marginal zone lymphoma (MZL) and their broader therapeutic implications. Chronic ibrutinib exposure generated a resistant MZL model that showed cross-resistance to BTK inhibitors and degraders, without evidence of multidrug resistance or genetic alterations. Integrated transcriptomic, epigenetic, and proteomic analyses revealed extensive reprogramming, including activation of PI3K/AKT, MAPK, and MYC pathways, repression of apoptosis and oxidative phosphorylation, and a prominent cytokine-secretory phenotype. Interleukin-16 (IL-16) emerged as a central mediator of resistance. IL-16 was transcriptionally upregulated, actively secreted, and sufficient to induce ibrutinib resistance across multiple CD9-positive models of MZL, mantle cell lymphoma, chronic lymphocytic leukemia (CLL), and activated B-cell-like diffuse large B-cell lymphoma. Serum IL-16 levels were elevated in ibrutinib-refractory CLL patients without BTK/PLCG2 mutations. Mechanistically, IL-16 engaged CD9-enriched membrane microdomains to activate PI3Kδ, thereby sustaining AKT and ERK signaling, stabilizing MYC, inducing NF-κB-dependent programs, and upregulating antiapoptotic effectors, including BFL1 (BCL2A1). Pharmacological or genetic disruption of the IL-16/CD9/PI3K axis restored sensitivity to BTK inhibitors and R-CHOP and abrogated IL-16-induced signaling in primary CLL samples. In conclusion, an IL-16/CD9-driven, epigenetically regulated survival pathway represents one possible mechanism of resistance to BTK inhibitors and chemoimmunotherapy, supporting therapeutic targeting of this axis in refractory B-cell lymphomas.

18 June 2025 in Cancers
Verified
Journal Article
Open access
PDF file
CTChiara Tarantelli
Chiara Tarantelli
FSFilippo Spriano
Filippo Spriano
ECElisa Civanelli
Elisa Civanelli
LALuca Aresu
Luca Aresu
GRGiorgia Risi
Giorgia Risi
Francesco BertoniFrancesco Bertoni
Francesco Bertoni
Background/Objectives: Reprogramming of the cellular metabolism is a hallmark of cancer, offering therapeutic opportunities to target cancer cell vulnerabilities for therapeutic purposes. 3-Bromopyruvate (3BP) is a small alkylating agent that functions as an anti-metabolite, targeting key substrates in cancer metabolism and demonstrating antitumor activity across multiple cancer types. However, unformulated 3BP is associated with significant toxicity. This study investigates the efficacy of KAT/3BP, a clinical derivative of 3BP currently in phase 1 trials for hepatocellular carcinoma, in preclinical lymphoma models. Results: In vitro, KAT/3BP exhibited cytotoxic activity across 12 lymphoma cell lines—including diffuse large B-cell lymphoma and mantle cell lymphoma—with a median IC50 of 3.7 μM. It also remained effective against lymphoma cell lines with acquired resistance to FDA-approved therapies. In vivo, treatment with KAT/3BP led to reduced tumor size in a syngeneic mouse model, with the combination of oral and intratumoral administration showing the greatest efficacy. Furthermore, KAT/3BP demonstrated synergistic activity when combined with standard lymphoma therapies such as bendamustine and R-CHOP. Conclusions: Our findings highlight the potential of KAT/3BP as a novel therapeutic option, either as a single agent or in combination regimens, for treating lymphomas.

11 February 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
ECEleonora Cannas
Eleonora Cannas
ARAlberto Arribas Romano
Alberto Arribas Romano
Luciano CascioneLuciano Cascione
Luciano Cascione
FGFrancesca Guidetti
Francesca Guidetti
ARAndrea Rinaldi
Andrea Rinaldi
Francesco BertoniFrancesco Bertoni
Francesco Bertoni
Cyclin-dependent kinase 9 (CDK9) drives transcriptional elongation and supports the expression of short-lived oncogenic and anti-apoptotic proteins such as MYC and MCL1. PRT2527 is a potent, selective CDK9 inhibitor currently in early clinical development. We evaluated its preclinical activity in marginal zone lymphoma (MZL) models, including cell lines with acquired resistance to BTK, PI3K, and BCL2 inhibitors. Short exposure (4 hours) to PRT2527 produced nanomolar cytotoxicity across all tested MZL cell lines, with efficacy maintained in resistant derivatives. Transcriptomic profiling of VL51 cells showed broad gene repression, including MYC, IRF4, NF-κB-related genes, and MCL1, alongside increased expression of HLA class II genes. Moreover, comparison with additional CDK inhibitors revealed a similar transcriptional repression signature, underscoring a conserved CDK-dependent regulatory network. Protein analyses confirmed rapid depletion of MCL1, MYC, RNA polymerase II, and IRF4. Flow cytometry validated increased HLA class II and decreased HLA class I surface expression. Combination studies demonstrated additive to synergistic effects with BTK inhibition (ibrutinib) or dual PI3K/BCL2 inhibition (copanlisib plus venetoclax), independent of baseline drug sensitivity. Mechanistically, these combinations may enhance apoptosis by concurrently suppressing survival signaling and transcriptional addiction. Analysis of patient samples revealed high CDK9 expression, further supporting the biological relevance and therapeutic rationale for targeting CDK9 in this disease. Our findings support the development of CDK9-based combination strategies for relapsed/refractory MZL and other B-cell malignancies, with an additional potential for integration with immunotherapies. Key Points: CDK9 inhibitor PRT2527 kills marginal zone lymphoma cells, regardless of whether they are resistant to other targeted drugs. PRT2527 boosts the effects of BTK, PI3K, and BCL2 inhibitors and alters immune-related gene expression. Draft of graphical

28 May 2026 in Cancers
Verified
Journal Article
Open access
PDF file
MPMaria Cristina Pirosa
Maria Cristina Pirosa
DHDagmar Hess
Dagmar Hess
FKFatime Krasniqi
Fatime Krasniqi
UNUrban Novak
Urban Novak
NMnicolas Mach
nicolas Mach
ASAnastasios Stathis
Anastasios Stathis
Background: This phase I trial aimed to assess the safety and preliminary activity of the combination of copanlisib with venetoclax in previously treated patients with B-cell non-Hodgkin lymphoma, excluding mantle-cell lymphoma patients. Methods: Intravenous copanlisib on days 1, 8, and 15 and oral venetoclax once daily (starting on day 2 of cycle 1, continuously) were administered in 28-day cycles up to a maximum of 12 cycles. Starting doses were 600 mg of venetoclax and 60 mg of copanlisib. Results: A total of seven patients were enrolled. The first two presented dose-limiting toxicities, five additional patients were treated at a lower dose level (45 mg of copanlisib and 400 mg of venetoclax), with no dose-limiting toxicities observed among three evaluable patients. The most frequent treatment-related adverse event of grade 3 or higher was neutropenia (n = 3), followed by thrombocytopenia (n = 2) and hypertension (n = 2). Four treatment-related serious adverse events occurred, including grade 3 febrile neutropenia in one patient and respiratory infections in three patients. Two patients had complete responses, and two had partial responses. Transcriptomic analysis of lymphoma samples showed enrichment of genes coding for proteins involved in B-cell receptor signaling in responding patients. The study was terminated prematurely due to a decision by the pharmaceutical company. Conclusions: Due to the limited sample size, no definite conclusions regarding safety or activity of the combination can be drawn. The two drugs could not be combined at their respective single-agent doses. Responses were observed in heavily pretreated patients. Transcriptomic analyses suggested a possible association between response and B-cell receptor signaling, which warrants further investigation.